

John A Hansen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/471357/publications.pdf>

Version: 2024-02-01

58
papers

3,500
citations

147801

31
h-index

144013

57
g-index

59
all docs

59
docs citations

59
times ranked

3148
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 1878-1887.	1.6	14
2	Genetic variants associated with cytomegalovirus infection after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2021, 138, 1628-1636.	1.4	7
3	Relevance of Plasma Matrix Metalloproteinase-9 for Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 759.e1-759.e8.	1.2	8
4	Inflammatory Cytokine Profile in Individuals with Inherited Chromosomally Integrated Human Herpesvirus 6. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 254-261.	2.0	7
5	Dickkopf-related protein 3 is a novel biomarker for chronic GVHD after allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2020, 4, 2409-2417.	5.2	14
6	Quality control project of NGS HLA genotyping for the 17th International HLA and Immunogenetics Workshop. <i>Human Immunology</i> , 2019, 80, 228-236.	2.4	27
7	Validation of single nucleotide polymorphisms in invasive aspergillosis following hematopoietic cell transplantation. <i>Blood</i> , 2017, 129, 2693-2701.	1.4	80
8	Predictive Value of Clinical Findings and Plasma Biomarkers after Fourteen Days of Prednisone Treatment for Acute Graft-versus-host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1257-1263.	2.0	29
9	Association of Plasma CD163 Concentration with De Novo Onset Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1250-1256.	2.0	38
10	Outcomes of hematopoietic cell transplantation using donors or recipients with inherited chromosomally integrated HHV-6. <i>Blood</i> , 2017, 130, 1062-1069.	1.4	65
11	The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 211-234.	2.0	328
12	Clinical and Genetic Determinants of Cardiomyopathy Risk among Hematopoietic Cell Transplantation Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1094-1101.	2.0	33
13	Genetic risk factors for sclerotic graft-versus-host disease. <i>Blood</i> , 2016, 128, 1516-1524.	1.4	18
14	Biomarker Panel for Chronic Graft-Versus-Host Disease. <i>Journal of Clinical Oncology</i> , 2016, 34, 2583-2590.	1.6	118
15	Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment. <i>Blood</i> , 2015, 126, 113-120.	1.4	110
16	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 780-792.	2.0	124
17	Human Leukocyte Antigen Class I and II Alleles and Cervical Adenocarcinoma. <i>Frontiers in Oncology</i> , 2014, 4, 119.	2.8	23
18	Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. <i>Blood</i> , 2014, 123, 786-793.	1.4	94

#	ARTICLE	IF	CITATIONS
19	A Novel Soluble Form of Tim-3 Associated with Severe Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1323-1330.	2.0	76
20	Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. <i>Blood</i> , 2013, 121, 5098-5103.	1.4	93
21	Defining genetic risk for graft-versus-host disease and mortality following allogeneic hematopoietic stem cell transplantation. <i>Current Opinion in Hematology</i> , 2010, 17, 483-492.	2.5	45
22	Outcome Following Hematopoietic Cell Transplantation for Patients with AML-CR1: Comparison between Matched-Sibling and Unrelated Allografts.. <i>Blood</i> , 2007, 110, 330-330.	1.4	4
23	T-cell alloreactivity in hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 24-27.	2.0	4
24	Correlation Between Disparity for the Minor Histocompatibility Antigen HA-1 and the Development of Acute Graft-Versus-Host Disease After Allogeneic Marrow Transplantation. <i>Blood</i> , 1999, 94, 2911-2914.	1.4	121
25	Transplantation of Marrow Cells From Unrelated Donors for Treatment of High-Risk Acute Leukemia: The Effect of Leukemic Burden, Donor HLA-Matching, and Marrow Cell Dose. <i>Blood</i> , 1997, 89, 4226-4235.	1.4	358
26	Allogeneic Peripheral Blood Stem Cell Transplantation May Be Associated With a High Risk of Chronic Graft-Versus-Host Disease. <i>Blood</i> , 1997, 90, 4705-4709.	1.4	303
27	Hematopoietic stem cell transplants from unrelated donors. <i>Immunological Reviews</i> , 1997, 157, 141-151.	6.0	99
28	Allogeneic Peripheral Blood Stem Cell Transplantation May Be Associated With a High Risk of Chronic Graft-Versus-Host Disease. <i>Blood</i> , 1997, 90, 4705-4709.	1.4	7
29	Development of registries of HLA-typed volunteer marrow donors. <i>Tissue Antigens</i> , 1996, 47, 460-463.	1.0	16
30	Marrow transplantation for Fanconi anaemia: conditioning with reduced doses of cyclophosphamide without radiation. <i>British Journal of Haematology</i> , 1996, 92, 699-706.	2.5	48
31	T-cell Receptor Polymorphisms in Tlingit Indians with Rheumatoid Arthritis. <i>Autoimmunity</i> , 1994, 19, 247-251.	2.6	2
32	Two new DR52-associated alleles, DRB1*1111 and *1312, identified by PCR/SSOP and confirmed by DNA sequencing. <i>Tissue Antigens</i> , 1994, 44, 52-56.	1.0	12
33	Role of the mixed lymphocyte culture (MLC) reaction in marrow donor selection: Matching for transplants from related haploidentical donors. <i>Tissue Antigens</i> , 1994, 44, 83-92.	1.0	17
34	Molecular diversity of the HLA-C locus in unrelated marrow transplantation. <i>Tissue Antigens</i> , 1994, 44, 93-99.	1.0	49
35	Analysis of HLA-B*44 alleles encoded on extended HLA haplotypes by direct automated sequencing. <i>Tissue Antigens</i> , 1994, 44, 211-216.	1.0	40
36	Fecundity before disease onset in women with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1993, 36, 7-14.	6.7	97

#	ARTICLE	IF	CITATIONS
37	A comparative study of HLA-DRB1 typing by standard serology and hybridization of non-radioactive sequence-specific oligonucleotide probes to PCR-amplified DNA. Tissue Antigens, 1993, 41, 86-93.	1.0	58
38	Recombinant granulocyte-macrophage colony stimulating factor followed by immunosuppressive therapy for aplastic anaemia. British Journal of Haematology, 1993, 85, 182-184.	2.5	9
39	Marrow Transplantation in Cancer Therapy.. Tohoku Journal of Experimental Medicine, 1992, 168, 333-343.	1.2	0
40	HLA antigens in Tlingit Indians with rheumatoid arthritis. Tissue Antigens, 1992, 40, 57-63.	1.0	51
41	Association of four HLA class III region genomic markers with HLA haplotypes. Tissue Antigens, 1991, 37, 191-196.	1.0	7
42	HLA-DR molecules enhance signal transduction through the CD3/Ti complex in activated T cells. Tissue Antigens, 1991, 38, 72-77.	1.0	10
43	Dw4(DRBI*0404) is a Dw4-dependent risk factor for rheumatoid arthritis Rethinking the "shared epitope" hypothesis. Tissue Antigens, 1991, 38, 145-151.	1.0	37
44	Polymorphism of HLA-DRw52-associated DRB1 genes as defined by sequence-specific oligonucleotide probe hybridization and sequencing. Tissue Antigens, 1991, 38, 169-177.	1.0	44
45	Signal transduction by HLA class II antigens expressed on activated T cells. European Journal of Immunology, 1991, 21, 123-129.	2.9	44
46	Homotypic aggregation of human cell lines by HLA class II-, class Ia- and HLA-G-specific monoclonal antibodies. European Journal of Immunology, 1991, 21, 2121-2131.	2.9	49
47	Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. British Journal of Haematology, 1989, 72, 567-572.	2.5	95
48	Human T cell activation: differential response to anti-CD28 as compared to anti-CD3 monoclonal antibodies. European Journal of Immunology, 1989, 19, 881-887.	2.9	44
49	Conservation of HLA class I private epitopes in macaques. Immunogenetics, 1988, 27, 356-362.	2.4	13
50	Tryptic peptide mapping identifies structural heterogeneity among six variants of HLA-B27. Immunogenetics, 1986, 23, 409-412.	2.4	11
51	Six variants of HLA-1327 identified by isoelectric focusing. Immunogenetics, 1986, 23, 24-29.	2.4	90
52	HLA-DQ heterogeneity among HLA-DRw11(5) haplotypes. Tissue Antigens, 1986, 28, 278-287.	1.0	1
53	Electrophoretic variation between class II molecules expressed on HLA-DRw8 homozygous typing cells reveals multiple distinct haplotypes. Immunogenetics, 1985, 21, 49-60.	2.4	27
54	Monoclonal antibody 9.3 and anti-CD11 antibodies define reciprocal subsets of lymphocytes. European Journal of Immunology, 1985, 15, 1164-1168.	2.9	83

#	ARTICLE	IF	CITATIONS
55	A monoclonal antibody recognizing a determinant shared by HLA-A2 and HLA-Aw69 (A28* variant). Tissue Antigens, 1985, 26, 114-120.	1.0	4
56	HLA-DR2 and DR4 further defined by two new HLA-D specificities (HTC) derived from Israeli Jewish donors: comparative study in Caucasian, Korean, Eskimo and Israeli populations. Tissue Antigens, 1984, 24, 197-205.	1.0	13
57	Hla antigens in yakima indians with rheumatoid arthritis. lack of association with hla-dw4 and hla-dr4. Arthritis and Rheumatism, 1982, 25, 1435-1439.	6.7	41
58	Involvement of the B-lymphoid system in chronic myelogenous leukaemia. Nature, 1980, 287, 49-50.	27.8	237